<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148222</url>
  </required_header>
  <id_info>
    <org_study_id>ProgenaBiome-019</org_study_id>
    <nct_id>NCT04148222</nct_id>
  </id_info>
  <brief_title>A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Lyme Disease</brief_title>
  <official_title>A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Lyme Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProgenaBiome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProgenaBiome</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to correlate microbiome sequencing data with information provided by
      patients and their medical records regarding Lyme Disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this Research Study is to better understand how the genetic information in
      subject's microbiome correlates to the information provided in surveys and in medical records
      regarding Lyme Disease
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of Microbiome to Lyme Disease via Relative Abundance Found in Microbiome Sequencing</measure>
    <time_frame>One year</time_frame>
    <description>Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized among specific disease types.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validation of Sequencing Methods</measure>
    <time_frame>One year</time_frame>
    <description>To validate the methods used to sequence samples</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lyme Disease</condition>
  <condition>Lyme Disease, Chronic</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients who have been diagnosed with Lyme Disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>There is no intervention for this study</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool Samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of Lyme Disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent, demonstrating that the patient understands the procedures
             required for the study and the purpose of the study

          2. Male or female patients of any age (interest is given to children to compare with
             mothers)

          3. Diagnosis of Lyme Disease

        Exclusion Criteria:

          1. Refusal to sign informed consent form

          2. History of bariatric surgery, total colectomy with ileorectal anastomosis or
             proctocolectomy.

          3. Postoperative stoma, ostomy, or ileoanal pouch

          4. Participation in any experimental drug protocol within the past 12 weeks

          5. Treatment with total parenteral nutrition

          6. Any clinically significant evidence of disease that could interfere with the subject's
             ability to enter the trial

          7. Inability to adequately communicate with the investigator or their respective designee
             and/or comply with the requirements of the entire study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Hazan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ProgenaBiome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Hazan, MD</last_name>
    <phone>8053390549</phone>
    <email>sabinehazan@aim.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan Daniels, MS</last_name>
    <phone>8053390549</phone>
    <email>msjordandaniels@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ProgenaBiome</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Hazan, MD</last_name>
      <phone>805-339-0549</phone>
      <email>sabinehazan@aim.com</email>
    </contact>
    <contact_backup>
      <last_name>Jordan Daniels, MS</last_name>
      <phone>805-339-0549</phone>
      <email>msjordandaniels@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine Hazan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lyme Disease</mesh_term>
    <mesh_term>Post-Lyme Disease Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

